Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat.
about
The study of a novel sorafenib derivative HLC-080 as an antitumor agentModeling and optimization of nanoemulsion containing Sorafenib for cancer treatment by response surface methodology.Biological evaluation of a novel sorafenib analogue, t-CUPMAntitumor activity of sorafenib-incorporated nanoparticles of dextran/poly(dl-lactide-co-glycolide) block copolymerA combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancerPolyphosphoester nanoparticles as biodegradable platform for delivery of multiple drugs and siRNA.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix.pH-Responsive carriers for oral drug delivery: challenges and opportunities of current platforms.NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer.Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.Influence of hydrophilic additives on the supersaturation and bioavailability of dutasteride-loaded hydroxypropyl-β-cyclodextrin nanostructures.Soluplus-coated colloidal silica nanomatrix system for enhanced supersaturation and oral absorption of poorly water-soluble drugs.Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery.Selective Nanoparticle Targeting of the Renal Tubules.The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism.In vitro and in vivo evaluation of redox-responsive sorafenib carrier nanomicelles synthesized from poly (acryic acid) -cystamine hydrochloride-D-α-tocopherol succinate.Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
P2860
Q28540521-A1F09E43-3F3C-4B0D-BEC5-A01C0557FA55Q30361130-783AB81C-DE02-466B-BCE5-B3C5A7D67277Q35448698-8E9D9A20-C471-4A2B-BC8B-E9002F508E3BQ35799514-722987C4-D0BF-42BB-9B46-E2EEBC8B4C1EQ36462972-77E23B2F-03A5-45EA-BF40-77FAF4F97E73Q36951503-18AF66A9-4B3F-4840-B5B3-4692C6BE7F25Q37669173-E28DF0BC-D7D7-4738-B271-8B30DFDDC301Q38082728-5BB46AB5-492E-46E2-A02E-29749585F21DQ38717731-BD22D145-1D46-4B66-B1F7-97D8E3E882C6Q38757836-C528D2FB-F516-4A1F-AEF6-C81B27443B3EQ38940292-5490141C-9692-4204-AAD0-9AB5B75F7689Q39026821-EBB2140D-133E-49FE-BF2A-3302AEE936C6Q39116687-A1D5DA0D-4ABE-4AFF-99D2-51B21AE81015Q41310160-7F23691A-C7E7-4585-BF49-3AE0E52F4669Q45339496-8E5672D2-3A2E-4E26-9F3F-FD076BA54A9DQ47719906-55B31111-AC71-4ABB-8748-00AFD69D2B6EQ48602509-B1BC9011-C6AF-49E8-A390-EB7AB22AD5A4Q50944606-51291F44-E626-4536-8B9D-067909BE2E80Q53572917-59D25C05-4631-4733-8D01-5C69F623E6A2Q53639202-DBFA3862-A5F8-4CD8-A53E-6DBF6A64B4B7
P2860
Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Bioavailability and pharmacoki ...... or oral administration to rat.
@en
Bioavailability and pharmacoki ...... or oral administration to rat.
@nl
type
label
Bioavailability and pharmacoki ...... or oral administration to rat.
@en
Bioavailability and pharmacoki ...... or oral administration to rat.
@nl
prefLabel
Bioavailability and pharmacoki ...... or oral administration to rat.
@en
Bioavailability and pharmacoki ...... or oral administration to rat.
@nl
P2093
P1476
Bioavailability and pharmacoki ...... or oral administration to rat.
@en
P2093
Jie-ming Fan
Qiang Zhang
Xue-qing Wang
Zeng-rong Jia
P304
P356
10.1016/J.IJPHARM.2011.08.003
P407
P577
2011-08-09T00:00:00Z